Ovarian cancer creates a suppressive microenvironment to escape immune elimination

Refika Yigit1, Leon F A G Massuger, Carl G Figdor

  • 1Department of Obstetrics and Gynecology (791), Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands. R.Yigit@obgyn.umcn.nl

Gynecologic Oncology
|February 11, 2010
PubMed
Abstract

Insights

New ovarian cancer immunotherapies are needed due to high mortality. Understanding the immune system

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Ovarian cancer has a high mortality rate with limited curative options for advanced or recurrent disease.
  • Immunotherapy shows promise in preclinical research but faces challenges in clinical application.
  • Developing novel therapeutic strategies is crucial for improving patient outcomes.

Purpose of the Study:

  • To review the complex interactions between ovarian cancer and the immune system.
  • To identify key mechanisms driving immune evasion in ovarian cancer.
  • To inform the development of more effective immunotherapeutic strategies.

Main Methods:

  • Literature search focused on ovarian cancer-immune system interactions.
  • Emphasis on studies with clinical outcome data.
  • Synthesis of findings to create a clinically relevant knowledge base.

Main Results:

  • Ovarian cancer involves a balance of immune-activating (e.g., tumor-infiltrating lymphocytes) and immune-suppressing factors.
  • Key suppressors include regulatory T-cells, plasmacytoid dendritic cells, B7-H4+ macrophages, IL10, TGF-beta, myeloid-derived suppressive cells, and VEGF.
  • These factors create an immunosuppressive tumor microenvironment, hindering anti-cancer immunity.

Conclusions:

  • Deeper understanding of ovarian cancer's immune microenvironment is essential for advancing immunotherapy.
  • Effective immunotherapy requires combining immune activation with suppression of immune-inhibitory mechanisms.
  • Shifting the tumor microenvironment from suppressive to active holds significant therapeutic potential.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...